US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

31.81

+0.41721.33%

Volume:2K

Turnover:74.00K

Market Cap:6.36M

PE:- -

High:31.87

Open:31.87

Low:31.81

Close:31.39

52wk High:43.01

52wk Low:27.40

Shares:200.00K

Float Shares:200.00K

Volume Ratio:1.60

T/O Rate:1.16%

Dividend:0.32

Dividend Rate:1.00%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

With the World's First Brain-Computer Interface Approval in Hand, How Far Is Neuracle From Profitability?

Scholar Rock Resubmits Apitegromab MAA to EMA for SMA Treatment

Scholar Rock Holding Corporation - Anticipates Chmp Opinion on Apitegromab Maa in H1 2027

THOMSON REUTERS

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) to European Medicines Agency (Ema) for Treatment of Children and Adults with Spinal Muscular Atrophy (Sma)

THOMSON REUTERS

Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50

THOMSON REUTERS

Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study

Brainco Interface Updates Prospectus, First-Half Loss Exceeds 65 Million Yuan

Anhui's First AI and Brain-Computer Interface Micro-Major Launches in Bengbu to Cultivate Talent for the Future Industry

Adherium Secures Non-Dilutive AUD$700,000 Loan to Support Working Capital

Xenon Pharmaceuticals Coverage Assumed by Guggenheim at Buy

Praxis Precision price target raised to $826 from $810 at BTIG

Scholar Rock Holding (SRRK) Dropped, What Is Driving Attention Now?

Simply Wall St.

Praxis Precision Med is Maintained at Buy by BTIG

Xenon Pharmaceuticals assumed with a Buy at Guggenheim

New Era in Neuroscience Begins: 2026 Nobel Prize in Medicine Awarded to Three Optogenetics Scientists

Nobel Prize in Physiology or Medicine 2026 Awarded to U.S. and German Pioneers of Optogenetics, Opening a New Era in Neuroscience

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02

Xenon Grants 17,850 Inducement Stock Options, 10,500 RSUs to New Hires Under NASDAQ Rule

Praxis Precision Medicines Grants 3,478 Inducement RSUs to 14 New Employees Under 2024 Plan

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IBRN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":31.81,"timestamp":1791569273410,"preClose":31.3928,"halted":0,"volume":2323,"delay":0,"changeRate":0.013289671517035676,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Trading","change":0.4172,"latestTime":"10-09 14:22:57 EDT","open":31.865,"high":31.865,"low":31.81,"amount":74004.888872,"amplitude":0.001752,"askPrice":32.52,"askSize":100,"bidPrice":31.2,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":31.3928,"sharesOutstanding":150000,"nav":31.865918,"aum":6373183.6,"dividendRate":0.010016,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.72,"preClose":31.3928,"latestTime":"16:10 EDT","volume":6,"amount":188.2912,"timestamp":1791490204224,"change":0.3272,"changeRate":0.010423,"amplitude":0},"volumeRatio":1.603593,"impliedVol":0.0879,"impliedVolPercentile":0.5259},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.603593,"shares":200000,"dividePrice":0.3186,"high":31.865,"amplitude":0.001752,"preClose":31.3928,"low":31.81,"week52Low":27.4025,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":31.81,"eps":0,"divideRate":0.010016,"volume":2323,"delay":0,"ttmEps":0,"open":31.865,"prevYearClose":32.3193,"prevWeekClose":32.552,"prevMonthClose":33.265,"prevQuarterClose":33.265,"fiveDayClose":32.552,"twentyDayClose":37.4262,"sixtyDayClose":38.0334},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1150577208","title":"With the World's First Brain-Computer Interface Approval in Hand, How Far Is Neuracle From Profitability?","url":"https://stock-news.laohu8.com/highlight/detail?id=1150577208","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150577208?lang=en_us&edition=fundamental","pubTime":"2026-10-08 21:02","pubTimestamp":1791464577,"startTime":"0","endTime":"0","summary":"On September 29, Neuracle, a leading player in China's brain-computer interface sector, updated its prospectus for a STAR Market IPO. According to the latest financial data disclosed by the company,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673074028","title":"Scholar Rock Resubmits Apitegromab MAA to EMA for SMA Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074028","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673074028?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:05","pubTimestamp":1791461130,"startTime":"0","endTime":"0","summary":"Scholar Rock resubmits apitegromab MAA to EMA for SMA treatmentScholar Rock resubmitted its EMA marketing authorization application for apitegromab to treat children and adults with spinal muscular at","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL87NWDn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SRRK","THNR","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673747750","title":"Scholar Rock Holding Corporation - Anticipates Chmp Opinion on Apitegromab Maa in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673747750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673747750?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:00","pubTimestamp":1791460803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA29VWNX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRRK","THNR","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673744880","title":"Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) to European Medicines Agency (Ema) for Treatment of Children and Adults with Spinal Muscular Atrophy (Sma)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673744880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673744880?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:00","pubTimestamp":1791460803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA29VWNX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THNR","BK4139","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079126","title":"Alkermes Plc : Leerink Partners Cuts Target Price to $45 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673079126?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457599,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U1FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","IBRN","PSIL","FBT","BK4139","ALKS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011796","title":"Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011796?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390650,"startTime":"0","endTime":"0","summary":"Alkermes plc ($ALKS) announced an update on their ongoing clinical study. Alkermes plc (ALKS) is running a mid-stage clinical study to test a new A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","PSIL","IBRN","MEDX","BK4139","ABVC","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196734573","title":"Brainco Interface Updates Prospectus, First-Half Loss Exceeds 65 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1196734573","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196734573?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:50","pubTimestamp":1791377433,"startTime":"0","endTime":"0","summary":"Stock investors look to the Jinlin Analyst Research Report for authoritative, professional, timely and comprehensive coverage to help uncover potential thematic opportunities. Brainco Interface...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179273018","title":"Anhui's First AI and Brain-Computer Interface Micro-Major Launches in Bengbu to Cultivate Talent for the Future Industry","url":"https://stock-news.laohu8.com/highlight/detail?id=1179273018","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179273018?lang=en_us&edition=fundamental","pubTime":"2026-10-07 18:01","pubTimestamp":1791367269,"startTime":"0","endTime":"0","summary":"Brain-computer interface technology, once confined to science fiction, is now advancing toward clinical application and industrial development.On September 30, the province's first \"AI and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673931066","title":"Adherium Secures Non-Dilutive AUD$700,000 Loan to Support Working Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673931066","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673931066?lang=en_us&edition=fundamental","pubTime":"2026-10-07 05:59","pubTimestamp":1791323947,"startTime":"0","endTime":"0","summary":"Adherium Ltd. ( ($AU:ADR) ) has issued an announcement. Adherium Limited, a global provider of connected respiratory medical devices and digital he...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adherium-secures-non-dilutive-aud700000-loan-to-support-working-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adherium-secures-non-dilutive-aud700000-loan-to-support-working-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SAPH","GDOC","AADR","MEDI","HART","AGNG","APIE","DINT","CURE","ARMH","IEHS","IBRN","MDTX","XT","PINK","CVY","LNGR","CROC","MDEV","BMED","RSPH","DIVL","FHLC","HRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673087056","title":"Xenon Pharmaceuticals Coverage Assumed by Guggenheim at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2673087056","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673087056?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:22","pubTimestamp":1791289320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","XENE","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055452","title":"Praxis Precision price target raised to $826 from $810 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055452?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:31","pubTimestamp":1791286309,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Praxis Precision (PRAX) to $826 from $810 and keeps a Buy rating on the shares. With relutrigine’s December ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-826-from-810-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-826-from-810-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","IBRN","IE00B2B36J28.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","PRAX","LU0889565916.HKD","IE00B4R5TH58.HKD","IE0002141913.USD","BK4139","IE00BJT1NW94.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673905552","title":"Scholar Rock Holding (SRRK) Dropped, What Is Driving Attention Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673905552","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673905552?lang=en_us&edition=fundamental","pubTime":"2026-10-06 18:22","pubTimestamp":1791282146,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding (SRRK) has drawn attention after its shares closed at US$43.40. The biopharma specialist is now valued at about US$5.29b and carries a value score of 3.\nRecent trading has been choppy for Scholar Rock Holding, with the share price falling 7.3% over the last day, 21.6% over the past month and 22.5% across 90 days. However, the 1-year total shareholder return of 9.9% and a very large 3-year total shareholder return hint that longer term momentum has been strong.\nScan beyond...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/scholar-rock-holding-srrk-dropped-what-is-driving-attention","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/scholar-rock-holding-srrk-dropped-what-is-driving-attention","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SRRK","IBRN","THNR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673058928","title":"Praxis Precision Med is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2673058928","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673058928?lang=en_us&edition=fundamental","pubTime":"2026-10-06 18:17","pubTimestamp":1791281820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU0889565916.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","PRAX","IBRN","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673841800","title":"Xenon Pharmaceuticals assumed with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2673841800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673841800?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:25","pubTimestamp":1791231927,"startTime":"0","endTime":"0","summary":"Guggenheim assumed coverage of Xenon Pharmaceuticals (XENE), which was previously covered by Yatin Suneja, with a Buy rating and $73 price target T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-assumed-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-assumed-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XENE","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165509474","title":"New Era in Neuroscience Begins: 2026 Nobel Prize in Medicine Awarded to Three Optogenetics Scientists","url":"https://stock-news.laohu8.com/highlight/detail?id=1165509474","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165509474?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198028,"startTime":"0","endTime":"0","summary":"Three scientists have been awarded the 2026 Nobel Prize in Physiology or Medicine for a breakthrough technique that turns algal proteins into switches for nerve cells.On October 5 local time, the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116668190","title":"Nobel Prize in Physiology or Medicine 2026 Awarded to U.S. and German Pioneers of Optogenetics, Opening a New Era in Neuroscience","url":"https://stock-news.laohu8.com/highlight/detail?id=1116668190","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116668190?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:16","pubTimestamp":1791195379,"startTime":"0","endTime":"0","summary":"Three scientists have been awarded the 2026 Nobel Prize in Physiology or Medicine for a breakthrough technology that converts algal proteins into a \"switch\" for nerve cells, a discovery set to usher...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDAXmain","FDXMmain","MNTL","IBRN","FDXSmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672974104","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2672974104","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672974104?lang=en_us&edition=fundamental","pubTime":"2026-10-03 06:23","pubTimestamp":1790979782,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $83,464.02Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Oct. 2, 2026.Sale price USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6fSlzc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $83,464.02","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","PSIL","MEDX","BK4139","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672467557","title":"Xenon Grants 17,850 Inducement Stock Options, 10,500 RSUs to New Hires Under NASDAQ Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2672467557","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672467557?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971282,"startTime":"0","endTime":"0","summary":"Xenon grants 17,850 inducement stock options, 10,500 RSUs to new hires under Nasdaq ruleXenon Pharmaceuticals issued inducement equity awards to eight new non-officer employees, totaling 17,850 share ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL4TdRtw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","LU0314104364.USD","IE00BN0W2V16.EUR","BCDF","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014013.SGD","IBRN","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","XENE","BK4585","BK4139","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4588","SG9999014039.USD","LU2210150020.SGD","NDAQ","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672746732","title":"Praxis Precision Medicines Grants 3,478 Inducement RSUs to 14 New Employees Under 2024 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2672746732","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672746732?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971276,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines grants 3,478 inducement RSUs to 14 new employees under 2024 planPraxis Precision Medicines granted restricted stock units covering 3,478 common shares to 14 new non-executiv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL8n5PWp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","BK4139","IE00B2B36J28.USD","LU0889565916.HKD","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","LU0109394709.USD","SG9999014005.SGD","IE00BQXX3D17.EUR","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","IBRN","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","PRAX","SG9999014039.USD","BCDF","LU0314104364.USD","IE0009355771.USD","IE0002141913.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00BQXX3C00.GBP","IE00BKPKM429.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749997","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749997","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749997?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971260,"startTime":"0","endTime":"0","summary":"VANCOUVER, BC and BOSTON, MA, Oct.  02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical devel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3374010/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","SBIO","XENE","LCLG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}